Clinical trials: Rifampicin Toxicity
Pulmonary Tuberculosis
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
In this trial, the investigators are assessing whether giving an increased dose of rifampicin to patients receiving the standard treatment for tuberculosis is safe and, when given for 4 months only, will also result in greater…
- Trial name
- RIFASHORT (NCT02581527)
- Testing
- Rifampicin, Isoniazid, Ethambutol
- Where
- 6 sites in Botswana, Guinea and 4 more
- Volunteers
- 672 people
- Sponsor
- St George's, University of London
Tuberculosis (TB), Isoniazid Toxicity
Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis
Tuberculosis (TB) remains a significant public health concern in Thailand and globally, especially in tropical regions, with pulmonary TB being predominant. Besides affecting the lungs, TB can also impact extrapulmonary organs.
- Conditions
- Tuberculosis (TB), Isoniazid Toxicity, Rifampicin Toxicity, Pyrazinamide Adverse Reaction
- Trial name
- NCT06484530
- Testing
- N acetyl cysteine
- Where
- Thailand
- Volunteers
- 116 people
- Sponsor
- Mahidol University